Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Combined With Inotuzumab Ozogamicin as First-Line Consolidation Therapy Bridging to HSCT in Ph+ ALL
NCT07443488Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of olverembatinib, inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
olverembatinibinotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07443488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443488.